2018 BMT Pharmacists Conference

Activity Announcement and Registration

For more information about the 2018 BMT Pharmacists Conference, visit www.cibmtr.org or www.asbmt.org. No brochures will be mailed this year.

PRINTABLE VERSION: 2018 BMT Pharmacist Conference Announcement

For more information about the 2018 BMT Pharmacists Conference, visit www.cibmtr.org or www.asbmt.org. No brochures will be mailed this year.

Pharmacist Continuing Education Information

Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Syntaxx Communications has assigned 13.25 contact hours (1.325 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This 2-day conference will incorporate 14 individual activity sessions that combined will fulfill the 13.25 hours of CE. The target audience for this accredited activity is pharmacists.

To receive continuing pharmacy education credit for the conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms. Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to http://www.nabp.net and click on CPE Monitor.

The Evaluation Survey must be completed within 30 days from the date the live program is completed in order to receive continuing education credit. Your NABP ePID number and date of birth (mm/dd) must be correctly provided. If incorrect information is uploaded into CPE Monitor and not rectified within 60 days of the program, a $225 fee will be charged as mandated by the ACPE. Please make sure your NABP ePID and date of birth(mm/dd) are correctly provided at the time you submit your program evaluation.

Faculty and Agenda
The full list of faculty and 2-day agenda are provided below.

Published
February 23, 2018 – February 24, 2021

Universal Activity Numbers
0299-9999-18-001-L01-P — 0299-9999-18-014-L01-P
This 2-day conference will be comprised of 14 individual sessions identified by 14 distinct UAN numbers.

Overall Conference Educational Objectives

After attending the 2018 BMT Pharmacists Conference, participants should be able to:

1. Summarize past and ongoing initiatives of the American Society of Blood and Marrow Transplantation (ASBMT) Pharmacy Special Interest Group.
2. Explain recent data regarding the management of hematologic malignancies and hematopoietic cell transplantation (HCT) presented at the American Society of Hematology meeting.
3. Analyze available options for the treatment of invasive fungal infection in HCT population.
4. Outline a treatment plan for a patients undergoing a HCT with Down Syndrome.
5. Examine the results of clinical trials supporting recently approved drugs, as well as ongoing research for emerging drugs, with indications pertinent to patients undergoing HCT.
6. Identify approaches to establishing a successful survivorship clinic to help manage the long-term complications of HCT, especially metabolic syndromes
7. Explain the treatment opportunities and barriers in the pharmacist-led management of medicinal marijuana and opioid prescriptive practice in patients who received a HCT.
8. Assess the data for initiating maintanence therapy in patients who have undergone HCT.
9. Choose the appropriate infection prophylaxis strategy for a patients undergoing a HCT.
10. Describe the biology and recent advances in the management of chronic graft-versus-host disease following allogeneic HCT.
11. Examine the benefits of different formal approaches to the management of CRS complications associated with cellular therapy in various institutions.
12. Describe the treatment plan and monitoring parameters for a patient receiving defibrotide.
13. Identify the advancing role of the pharmacist in HCT patient management, healthcare changes in the new political landscape, issues relevant to our daily practices, and tools needed to become a patient advocate.

Program Evaluation Forms

The 2018 BMT Tandem Meetings online Evaluation Program is now open through Tuesday, March 27, 2018. If you wish to claim continuing education credit, you may access the evaluations through the Mobile App or Online Agenda. Once you access the mobile app or online agenda, please create an account and sign in using the same email address you used during the registration process (using an alternative email address will preclude you from accessing the evaluations). Once you have successfully logged in, select sessions attended to complete evaluations. Sessions with available evaluations will be marked with the following icon: Evaluation Survey Icon_image001 Once you see this icon, click on the Session Title to access the Evaluate button.

Once the Session Evaluations are complete, be sure to complete the “Overall Meeting Evaluation”. Credit will not be issued without completion of the “Overall Meeting Evaluation”. Please be sure to download your certificates from the “Certificate Summary” tab once both the overall meeting and session evaluations have been submitted.

Requests for Certificates after March 27 will incur a $60 processing charge. An electronic copy of the Certificate will be filed with the Medical College of Wisconsin. Certificates will not be mailed.

For problems or issues related to continuing pharmacy education, please contact Julie Marino at Syntaxx
Communications:

E-mail: jmarino@syntaxxcomm.com
Phone: 678.584.9503 or 404.969,6416
Mail: 305 W Country Dr, Johns Creek, GA 30097

*Fees
No additional fee for the 2-day (February 23, 2018 – February 24, 2018) BMT Pharmacists Conference will be charged to attendees requesting continuing pharmacy education (CPE) credit. Registration for the BMT Tandem Meetings (February 21, 2018 – February 25, 2018) covers attendance and CPE for any/all CPE activities.

Registration Type
By 10/3/17, After 10/3/17, After 1/25/18 (onsite)

Member (ASBMT & CIBMTR)
$650, $750, $950

Member (ASBMT or CIBMTR Only)
$750, $850, $1,050

Non-Member
$950, $1,050, $1,300

Allied Health Professionals
$430, $570, $670

Fellows In-Training
$399. $425, $480

*See attached Registration Fee Schedule for the 2018 BMT Tandem Meetings

Required Computer Hardware/Software
Educational materials and handouts will be posted on the ASBMT and CIBMTR Web sites and available for registrants to print before the activities of this 2-day conference commence. Registrants are encouraged to print the materials before arriving at the conference. Printers will not be available onsite for conference attendee use. A business center will be available to those willing to pay for copies.

Registrants will need an Internet connection in order to use the mobile application for the ARS/live polling portions of the program or the Web site (using electronic devices, such as a PC, Mac, tablet, or smart phone). Please note that PC and Apple computers do not support the Bravura Technologies Mobile Application that will be used for the ARS/live polling portion of each activity. The application to search and download for an IOS/Android tablet/mobile phone is 2018 BMT TANDEM.
updated 9.26.17

AGENDA

DAY 1 – Friday, February 23, 2018

8:15 am – 8:30 am
Welcome and Overview
Colleen Timlin, PharmD

8:30 am – 9:45 am
ASH Update
Elizabeth DiMaggio, PharmD

9:45 am – 10:15 am
Challenging Cases – HCT in Down Syndrome
Jamie Rouch, PharmD

10:15 am – 10:30 am
Morning break

10:30 am – 11:00 am
BMT Pharmacists SIG update
LeAnne Kennedy, PharmD

11:00 am – 12:00 pm
Survivorship – Metabolic Syndrome
K. Scott Baker, MD

12:00 pm – 1:15 pm
Lunch Break
 
1:15 pm – 2:15 pm
New and Emerging Drugs
Arpita Gandhi, PharmD

2:15 pm – 2:30 pm
Afternoon break
 
2:30pm – 3:30 pm
Invasive Fungal Infections
Samuel Aitkens, PharmD

3:30 pm – 4:30 pm
Maintenance Therapy Strategies Post-Transplant
Kelly Hawks, PharmD

4:30 pm – 5:45 pm
Best Pharmacy Abstracts
10626 – 8A-Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemiac – Katie Gatwood, PharmD

10658: 8B-Maintenance Azacitidine after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies – Kathryn T. Maples, PharmD

11305: 8C-A Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients – Lauren Ice, PharmD

11575: 8D-Amlodipine and Calcineurin Inhibitor Induced Nephrotoxicity Following Allogeneic Hematopoietic Stem Cell Transplant – Ryan Jensen, PharmD

DAY 2 – Saturday, February 24, 2018

8:15 am – 8:30 am
Welcome and Overview
Terri Lynn Shigle, PharmD

8:30 am – 9:30 am
Pharmacy Advocacy
Rebecca Tombleson, PharmD; Justin Arnall, PharmD

9:30 am – 10:00 am
Challenging Cases – Defibrotide for Management of Veno-Occlusive Disease
Katie Gatwood, PharmD

10:00 am – 10:15 am
Morning break
 
10:15 am- 11:15 am
Infection Prophylaxis in HCT Patients
Melissa Johnson, PharmD

11:15 am – 12:00 pm
Pharmacy Award Presentations

12:00 pm – 1:15 pm
Lunch Break
 
1:15 pm – 2:15 pm
Cannabinoid Consult Service:
Fostering Safe Use of Medicinal Marijuana in the Hospital Setting
Amy Carver, PharmD

2:15 pm – 2:30 pm
Afternoon break
 
2:30 pm – 3:30 pm
Biology of cGVHD
Paul Martin, MD

3:30 pm – 4:45 pm
Best Practices: An Update on CAR T Cells and CRS Management with Cellular Therapy
Wendy Covert, PharmD
Christina A Bachmeier, PharmD
Craig Freyer, PharmD

Financial Support
Jazz Pharmaceuticals, Incyte Corporation, Celgene Corporation

Financial Disclosures
(All presentations will be fully vetted by an objective, clinical peer group and Syntaxx Communications, the ACPE accredited, CPE provider)

Katie Gatwood, PharmD: Jazz Pharmaceuticals: Honoraria, Advisory Board (this presentation will be carefully vetted to make sure there is no bias).
Samuel Aitken, PharmD: Advisory Board and Research Support; Melinta Therapeutics/Cempra: Advisory Board; The Medicines Company: Advisory Board; Accelerate Diagnostics: Consultancy; Achaogen: Advisory Board; Zavante: Advisory Board; Merck: Other: Speaker’s bureau, Advisory Board
Melissa Johnson, PharmD: Charles River Laboratories: Principal Investigator, Research Funding; UpToDate, LLC: Author, Royalty; Merck & Co: Principal Investigator, Research Funding (Both sources of research funding goes to her institution)
Paul Martin, MD: Neovii (Fresenius): Clinical Investigator, Research Funding; Pfizer: DSMB Member, Consultancy; Procter and Gamble: Stock, Ownership Interest (None of these financial arrangements is related to his discussion of treatment for acute GVHD. )
Craig Freyer, PharmD: Astellas Pharma: Speaker Bureau, Honoraria (This commercial interest does not relate to the content of this presentation. He receives speaking honoraria for presentations on invasive fungal infections, which is not relevant to this presentation.)
John M. McCarty, MD: [Dr. McCarty is a collaborator on a Best Abstracts presention (Kathryn Maples, PhamdD)] Speakers Bureau, Principle Investigator, Honoraria and Research Funding: Celgene (Celgene manufactures azacitidine).

There are no other known conflicts of interest at this time; investigational/off-label use of drugs may be discussed.